Pembrolizumab-induced type 1 diabetes.
Ariana MaiaDaniela M SoaresSofia AzevedoTeresa PereiraCláudia AmaralPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
This case highlights the importance of clinical suspicion and glycaemic monitoring as an integral part of treatment protocols in patients on pembrolizumab and other immune checkpoint inhibitors. Additional research and investigation into the underlying mechanisms of this condition are necessary to identify potential screening tests for individuals at higher risk of developing DM and to guide the implementation of management and preventive strategies for ketoacidosis complication.
Keyphrases
- type diabetes
- end stage renal disease
- ejection fraction
- primary care
- advanced non small cell lung cancer
- chronic kidney disease
- healthcare
- newly diagnosed
- glycemic control
- prognostic factors
- insulin resistance
- cardiovascular disease
- peritoneal dialysis
- patient reported outcomes
- high glucose
- oxidative stress
- epidermal growth factor receptor
- patient reported